If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Most of the run-through schemes are in stand-alone specialties (e.g., radiology, public health, histopathology), but there are also a few traditionally surgical specialities which can be entered directly without completing core surgical training (e.g., neurosurgery, obstetrics & gynaecology, ophthalmology). The length of this training varies; for example, general practice is three years while radiology is five years. The UK grade equivalent of a US fellow in medical/surgical sub-specialties is the specialty registrar (ST3–ST9) grade of sub-specialty training. However, while US fellowship programmes are generally 2–3 years in duration after completing the residency, UK trainees spend 4–7 years. This generally includes service provision in the main specialty; this discrepancy lies in the competing demands of NHS service provision, and UK postgraduate training stipulating that even specialist registrars must be able to accommodate the general acute medical take—almost equivalent to what dedicated attending internists perform in the United States (they still remain minimally supervised for these duties). In 2024, the British Medical Association (BMA) advocated for all junior doctors to be renamed residents to prevent the confusion between resident doctors and medical students that terms such as "junior doctors" and "doctors in training" produce.
Efficient oxidation reactions of precursors of important basic chemicals are of particular technical interest. For example, ε-caprolactam can be prepared using NHPI from the so-called KA oil ("ketone-alcohol" oil, a mixture of cyclohexanol and cyclohexanone) which is obtained during the oxidation of cyclohexane. The reaction proceeds via cyclohexanol hydroperoxide, which reacts with ammonia to give peroxydicyclohexylamine followed by a rearrangement in the presence of catalytic amounts of lithium chloride.
In CYP2D6 extensive metabolizers, the half-lives of 4-hydroxyatomoxetine and N-desmethylatomoxetine are similar at around 6 to 8 hours, whereas in CYP2D6 poor metabolizers, the half-life of N-desmethylatomoxetine is much longer at around 33 to 40 hours. Atomoxetine levels in cerebrospinal fluid (CSF) with atomoxetine at a dosage of 80 mg/day were 6.6 ng/mL at 8 hours post-dose and 1.4 ng/mL at 24 hours post-dose following 2 weeks of administration.
== January 25, 1982 (Monday) == In a speech in Asmara, Ethiopia's President Mengistu Haile Mariam announced his "Red Star Campaign", a military operation to destroy the Eritrean People's Liberation Front and the Tigray People's Liberation Front secessionist groups in Eritrea Province. The campaign would begin on February 15, 1982, and last for almost five months, until July 5, with at least 10,000 Ethiopian and 4,000 Eritrean soldiers killed. Propaganda Due (P2), the controversial Italian Masonic lodge, was formally dissolved after 105 years of operation. The Amol uprising, an unsuccessful rebellion by Siamak Zaim of the League of Iranian Communists, was launched against the Islamic Republic government in Iran's Mazandaran province. The R. E. Ginna Nuclear Power Plant near Ontario, New York in the U.S. sustained a nuclear accident when a tube on a steam generator ruptured and radioactive steam was released for 93 minutes before the problem was fixed. Born: Heather Hardy, enshrinee in the International Women's Boxing Hall of Fame as world female featherweight champion of the World Boxing Organization from 2018 to 2019; in Brooklyn, New York City Died: Mikhail Suslov, 79, Deputy General Secretary of the Soviet Communist Party and the Party's second only to General Secretary and President Leonid Brezhnev. William Russel Huber, 79, U.S. Navy sailor and recipient of the Medal of Honor Mildred Christman, 86, American rodeo bronco riding champion, trick rider, and actress
Matthew turning up after 20 years and wanting a relationship with her is "too much for Ari to handle", especially with Ari knowing how he took advantage of Mia. Chloe forges a bond with Matthew, which angers Mia and Ari, who later punches Matthew during an argument. Matthew realises he can use Ari's criminal record to his advantage and warns Mia to back off, or he will report Ari's assault to the police. Matthew tries to take Chloe away from Mia by offering her the tuition to a prestigious college in the city. Ari believes that telling Chloe the truth about her conception will keep her in the Bay. Kipa-Williams stated: "Ari respects Mia's choice not to tell Chloe about what happened with Matthew, but he also wants to keep her from making decisions that may affect her wellbeing." After Chloe accepts Matthews's offer, Mia tells her the truth and Chloe finally understands Mia's behaviour towards Matthew. Ari later receives a phone call from Chloe asking for his help as Matthew has turned up at the house. Kipa-Williams pointed out that Ari believes Matthew is "unpredictable and dangerous" and would do anything to protect Chloe and Mia. The story sees Chloe accidentally kill Matthew when she hits him over the head with a brick to protect Mia.
Sources: en.wikipedia.org
=== Unproven treatments === Botulinum toxin A injections, platelet-rich plasma injections and prolotherapy remain controversial. Dry needling is under consideration. A systematic review of available research found limited evidence of effectiveness. The studies were reported to be inadequate in quality and too diverse in methodology for a firm conclusion.However, later evidence suggested that dry needling may help reduce pain and improve function, particularly over longer follow-up periods. A combination of plantar fasciitis stretching and botulinum toxin showed an increase in improvement and functionability.
Occupational therapy may implement changes to a person's environment, both at home or work, to increase the individual's function and accessibility. Furthermore, it addresses psychosocial changes and cognitive decline that may accompany MD, and provides support and education about the disease to the family and patient.
Pasteur's research led to Ignaz Semmelweis and Joseph Lister researching the importance of sanitized hands in medical work. In the 1840s, Semmelweis' observations and ideas surrounding sanitary techniques were rejected and his book on the topic condemned by the medical community due to its conflict with the prevailing theory and practice of humorism at the time. After Lister's publications, which supported hand washing and sanitation with germ theory, doctors started sanitizing their hands in the 1870s; mandatory handwashing was not incorporated into common health practice until as late as the 1980s. The discovery of the connection of microorganisms to disease came later in the nineteenth century, when Italian anatomist Filippo Pacini isolated the cholera bacterium Vibrio cholerae in 1854 in Florence during the Asiatic Cholera Pandemic of 1846–63 and clearly linked the presence of the bacterium in the intestinal mucosa of dead cholera patients to the disease. Although Pacini's work was available to the international scientific community via French and English translations, the discovery of the cholera-causing agent is often attributed to the German physician Robert Koch who rediscovered it in 1884. Koch is credited for introducing the science of microorganisms including bacteria to the medical field. Koch, a pioneer in medical microbiology, worked on cholera, anthrax and tuberculosis. In his research into tuberculosis Koch finally proved the germ theory, for which he received a Nobel Prize in 1905.
=== Phylogenetic relationships and molecular studies === Modern taxonomy places X. parietina in the family Teloschistaceae, order Teloschistales, within the class Lecanoromycetes (lichenized Ascomycota). It is closely related to other orange lichens such as those in the genera Caloplaca, Teloschistes, and other members of the Xanthorioid clade of the Teloschistaceae. Molecular studies have helped clarify its phylogenetic relationships. For example, DNA sequence analyses provided evidence that X. parietina is genetically distinct from Xanthoria aureola, another yellow coastal lichen that had sometimes been considered merely a variety or form of X. parietina. Their study confirmed that X. aureola is a separate species, not conspecific with X. parietina. Microscopic studies have established Xanthoria parietina as the prototype species for the "Teloschistes-type" ascus, a structural category characterized by an apically thickened, strongly amyloid outer layer and a dome-like apex that splits longitudinally during spore release. This ascus type, originally described in members of Xanthoria, Teloschistes, and related genera, differs from the "Lecanora-type" by lacking a specialized discharge mechanism and instead relying on simple rupture for ascospore release. Early electron microscopy investigations of X. parietina helped clarify the functional nature of this ascus and its distinction from other ascus types found in lichenized fungi.
Sources: en.wikipedia.org
The Windscale fire brought the need for testing of the land downwind for radioactive material contamination, and this is how it was found. An estimate of 8.8 terabecquerels (240 Ci) of polonium-210 has been made. It has also been suggested that Irène Joliot-Curie's 1956 death from leukaemia was owed to the radiation effects of polonium. She was accidentally exposed in 1946 when a sealed capsule of the element exploded on her laboratory bench. As well, several deaths in Israel during 1957–1969 have been alleged to have resulted from 210Po exposure. A leak was discovered at a Weizmann Institute laboratory in 1957. Traces of 210Po were found on the hands of Professor Dror Sadeh, a physicist who researched radioactive materials. Medical tests indicated no harm, but the tests did not include bone marrow. Sadeh, one of his students, and two colleagues died from various cancers over the subsequent few years. The issue was investigated secretly, but there was never any formal admission of a connection between the leak and the deaths. The Church Rock uranium mill spill 16 July 1979 is reported to have released polonium-210. The report states animals had higher concentrations of lead-210, polonium-210 and radium-226 than the tissues from control animals.
The integration of different regulatory signals by gonadotropes results in the coordinated control of production and secretion of gonadotropins to respond and control sexual maturation and reproductive functions.
== Parallel evolution of cardiotonic steroid resistance in vertebrates == Several studies have detailed the evolution of cardiotonic steroid resistance of the alpha-subunit gene family of Na/K-ATPase (ATP1A) in vertebrates via amino acid substitutions most often located in the first extracellular loop domain. Amino acid substitutions conferring cardiotonic steroid resistance have evolved independently many times in all major groups of tetrapods. ATP1A1 has been duplicated in some groups of frogs and neofunctionlised duplicates carry the same cardiotonic steroid resistance substitutions (Q111R and N122D) found in mice, rats and other muroids.
== Recognition == In 1999, the University of Oulu collagen research group received, for the second time, the Finnish Science Award, divided amongst the group's members. In addition to Ala-Kokko, the group included professors Kari Kivirikko and Taina Pihlajaniemi. In 2001 she received the Norwegian Anders Jahre Prize for Young Scientists.
In 2023, it was the 246th most commonly prescribed medication in the United States, with more than 1 million prescriptions. It is available as a generic medication. In 2023, the combination of dexamethasone with neomycin and polymyxin B was the 260th most commonly prescribed medication in the United States, with more than 1 million prescriptions; and the combination of dexamethasone with ciprofloxacin was the 283rd most commonly prescribed medication in the United States, with more than 700,000 prescriptions;
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.